Camden National Bank Buys 7,879 Shares of Zoetis Inc. $ZTS

Camden National Bank raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 12.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,082 shares of the company’s stock after acquiring an additional 7,879 shares during the quarter. Camden National Bank’s holdings in Zoetis were worth $8,944,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC grew its stake in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC grew its stake in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the last quarter. Finally, Glenview Trust co grew its stake in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after acquiring an additional 506 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Bank of America lifted their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Stifel Nicolaus lowered their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Friday, May 22nd. UBS Group lowered their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. Finally, Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Six analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $133.92.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Kaplan Fox, Levi & Korsinsky, Robbins LLP, Frank R. Cruz, and Robbins Geller, announced or reminded investors about a class action lawsuit tied to Zoetis securities purchases between January 14, 2025 and May 6, 2026. These updates highlight the July 27, 2026 lead-plaintiff deadline and keep the litigation risk in focus. Article Title
• Negative Sentiment: One lawsuit notice alleges Zoetis’ risk disclosures were too generic and failed to warn investors about known safety and competition issues, suggesting possible shareholder harm and adding to uncertainty around the company’s legal and operational outlook. Article Title
• Neutral Sentiment: A Yahoo Finance item flagged Zoetis as one of the most oversold S&P 500 stocks so far in 2026, which may reflect weak sentiment but does not itself provide a new company-specific catalyst. Article Title

Insiders Place Their Bets

In related news, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $77.61 on Tuesday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $172.23. The business has a 50-day moving average price of $103.52 and a 200 day moving average price of $116.71. The firm has a market cap of $32.54 billion, a PE ratio of 12.87, a P/E/G ratio of 1.27 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 EPS. Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.